These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 36103273)
1. Higher Cell-Mediated Immune Responses in Patients With Inflammatory Bowel Disease on Anti-TNF Therapy After COVID-19 Vaccination. Caldera F; Farraye FA; Necela BM; Cogen D; Saha S; Wald A; Daoud ND; Chun K; Grimes I; Lutz M; Van Helden SR; Swift MD; Virk A; Bharucha AE; Patel TC; Gores GJ; Chumsri S; Hayney MS; Knutson KL Inflamm Bowel Dis; 2023 Aug; 29(8):1202-1209. PubMed ID: 36103273 [TBL] [Abstract][Full Text] [Related]
2. Higher and Sustained Cell-Mediated Immune Responses After 3 Doses of mRNA COVID-19 Vaccine in Patients With Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy. Caldera F; Rolak S; Farraye FA; Necela BM; Cogen D; Zona EE; Schell TL; Ramirez OR; Almasry M; Chun K; Hayney MS; Knutson KL Clin Transl Gastroenterol; 2024 Apr; 15(4):e00688. PubMed ID: 38349178 [TBL] [Abstract][Full Text] [Related]
3. COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study. Alexander JL; Liu Z; Muñoz Sandoval D; Reynolds C; Ibraheim H; Anandabaskaran S; Saifuddin A; Castro Seoane R; Anand N; Nice R; Bewshea C; D'Mello A; Constable L; Jones GR; Balarajah S; Fiorentino F; Sebastian S; Irving PM; Hicks LC; Williams HRT; Kent AJ; Linger R; Parkes M; Kok K; Patel KV; Teare JP; Altmann DM; Goodhand JR; Hart AL; Lees CW; Boyton RJ; Kennedy NA; Ahmad T; Powell N; Lancet Gastroenterol Hepatol; 2022 Nov; 7(11):1005-1015. PubMed ID: 36088954 [TBL] [Abstract][Full Text] [Related]
4. Humoral Immunogenicity After Vaccination Against SARS-CoV-2 Infection in Inflammatory Bowel Disease Patients Under Immunosuppressive Therapy: Should We Prioritize an Additional Booster Injection? Macedo Silva V; Lima Capela T; Freitas M; Cúrdia Gonçalves T; Boal Carvalho P; Dias de Castro F; João Moreira M; Cotter J Inflamm Bowel Dis; 2023 Feb; 29(2):268-273. PubMed ID: 36099059 [TBL] [Abstract][Full Text] [Related]
5. Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2. Woelfel S; Dütschler J; König M; Graf N; Oikonomou V; Krieger C; Truniger S; Franke A; Eckhold A; Forsch K; Wyss J; Krupka N; Albrich W; Frei N; Geissler N; Schaub P; ; Friedrich M; Misselwitz B; Korte W; Bürgi JJ; Brand S Aliment Pharmacol Ther; 2023 Jan; 57(1):103-116. PubMed ID: 36307899 [TBL] [Abstract][Full Text] [Related]
6. Anti-tumor necrosis factor therapy is associated with attenuated humoral response to SARS-COV-2 vaccines in patients with inflammatory bowel disease. Bordalo Ferreira F; Rafael MA; Coimbra L; Boavida N; Arrobas F; Pereira Correia F; Martins Figueiredo L; Carvalho E Branco J; Carvalho Lourenço L; Santos L; Oliveira AM Vaccine; 2023 Jun; 41(26):3862-3871. PubMed ID: 37202269 [TBL] [Abstract][Full Text] [Related]
7. Use of Tumor Necrosis Factor-α Antagonists Is Associated With Attenuated IgG Antibody Response Against SARS-CoV-2 in Vaccinated Patients With Inflammatory Bowel Disease. Otten AT; Bourgonje AR; Horinga PP; van der Meulen HH; Festen EAM; van Dullemen HM; Weersma RK; van Leer-Buter CC; Dijkstra G; Visschedijk MC Front Immunol; 2022; 13():920333. PubMed ID: 35865529 [TBL] [Abstract][Full Text] [Related]
8. Impact of Holding Immunosuppressive Therapy in Patients with Inflammatory Bowel Disease Around mRNA COVID-19 Vaccine Administration on Humoral Immune Response and Development of COVID-19 Infection. Motwani KK; Hashash JG; Farraye FA; Kappelman MD; Weaver KN; Zhang X; Long MD; Cross RK J Crohns Colitis; 2023 Nov; 17(10):1681-1688. PubMed ID: 37232444 [TBL] [Abstract][Full Text] [Related]
9. Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study. Cerna K; Duricova D; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kostrejova M; Teplan V; Vasatko M; Kastylova K; Lukas M Inflamm Bowel Dis; 2022 Oct; 28(10):1506-1512. PubMed ID: 34849919 [TBL] [Abstract][Full Text] [Related]
10. Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type. Jørgensen KK; Høivik ML; Chopra A; Benth JŠ; Ricanek P; Moum PB; Jyssum I; Bolstad N; Warren DJ; Vaage PJT; Munthe PLA; Lundin PKEA; Anisdahl K; Syversen SW; Goll GL; Lund-Johansen F; Medhus AW; Jahnsen PJ Scand J Gastroenterol; 2023; 58(8):874-882. PubMed ID: 36788656 [TBL] [Abstract][Full Text] [Related]
11. The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients. Alexander JL; Mullish BH; Danckert NP; Liu Z; Olbei ML; Saifuddin A; Torkizadeh M; Ibraheim H; Blanco JM; Roberts LA; Bewshea CM; Nice R; Lin S; Prabhudev H; Sands C; Horneffer-van der Sluis V; Lewis M; Sebastian S; Lees CW; Teare JP; Hart A; Goodhand JR; Kennedy NA; Korcsmaros T; Marchesi JR; Ahmad T; Powell N EBioMedicine; 2023 Feb; 88():104430. PubMed ID: 36634565 [TBL] [Abstract][Full Text] [Related]
12. Reduced Serological Response to COVID-19 Vaccines in Patients with IBD is Further Diminished by TNF Inhibitor Therapy; Early Results of the VARIATION study [VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON]. Doherty J; Morain NO; Stack R; Girod P; Tosetto M; Inzitiari R; Sheridan J; Cullen G; McDermott E; Buckley M; Horgan G; Mulcahy H; Ryan EJ; Daghfal D; Doran P; Morain CO; Doherty GA J Crohns Colitis; 2022 Sep; 16(9):1354-1362. PubMed ID: 35176770 [TBL] [Abstract][Full Text] [Related]
13. Humoral Immunogenicity of mRNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease and Healthy Controls. Caldera F; Knutson KL; Saha S; Wald A; Phan HS; Chun K; Grimes I; Lutz M; Hayney MS; Farraye FA Am J Gastroenterol; 2022 Jan; 117(1):176-179. PubMed ID: 34797219 [TBL] [Abstract][Full Text] [Related]
14. Factors Affecting Initial Humoral Immune Response to SARS-CoV-2 Vaccines Among Patients With Inflammatory Bowel Diseases. Kappelman MD; Weaver KN; Zhang X; Dai X; Watkins R; Adler J; Dubinsky MC; Kastl A; Bousvaros A; Strople JA; Cross RK; Higgins PDR; Ungaro RC; Bewtra M; Bellaguarda EA; Farraye FA; Boccieri ME; Firestine A; Chun KY; Fernando M; Bastidas M; Zikry M; Long MD Am J Gastroenterol; 2022 Mar; 117(3):462-469. PubMed ID: 35029167 [TBL] [Abstract][Full Text] [Related]